공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

CMP(Comprehensive Metabolic Panel) 시장 : 성장, 동향, 예측

Comprehensive Metabolic Panel Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

리서치사 Mordor Intelligence Pvt Ltd
발행일 2021년 03월 상품 코드 922079
페이지 정보 영문
가격
US $ 4,250 ₩ 4,788,000 PDF (Single User License)
US $ 4,750 ₩ 5,352,000 PDF (Team License: Up to 7 Users)
US $ 6,000 ₩ 6,760,000 PDF (Site License)
US $ 7,500 ₩ 8,451,000 PDF (Corporate License)


CMP(Comprehensive Metabolic Panel) 시장 : 성장, 동향, 예측 Comprehensive Metabolic Panel Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)
발행일 : 2021년 03월 페이지 정보 : 영문

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 CMP(Comprehensive Metabolic Panel) 시장을 조사했으며, 시장의 개요, 종류, 최종사용자, 지역별 시장 동향, 시장 규모의 추이와 예측, 시장 촉진·저해요인 및 시장 기회 분석, 경쟁 구도, 주요 기업의 개요 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

  • 조사 성과
  • 조사의 전제조건
  • 조사 범위

제2장 조사 방법

제3장 주요 요약

제4장 시장 역학

  • 시장 개요
  • 성장 촉진요인
  • 성장 저해요인
  • Porter's Five Forces 분석
    • 신규 진출의 위협
    • 소비자의 교섭력
    • 공급업체의 교섭력
    • 대체품의 위협
    • 경쟁 기업간 경쟁 관계

제5장 시장 세분화

  • 테스트 유형별
    • 단백질
    • 신장 검사
    • 전해질
    • 간기능 검사
    • 글루코오스
    • 기타
  • 질환별
    • 신장병
    • 당뇨병
    • 간질환
    • 기타
  • 최종사용자별
    • POC(Point of Care) 센터
    • 시험기관
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 중동·아프리카
    • 남미

제6장 경쟁 구도

  • 기업 개요
    • Quest Diagnostics
    • Laboratory Corporation of America Holdings
    • Sonic Healthcare Limited
    • Synlab Hrvatska
    • Charles River Laboratories, Inc.
    • ARUP Laboratories.
    • NeoGenomics Laboratories, Inc.
    • Genoptix, Inc.
    • CENTOGENE NV
    • UNIPATH

제7장 시장 기회 및 향후 전망

KSA 20.03.17

The global comprehensive metabolic panel market is poised to grow at a CAGR of 7.2% during the forecast period. The market is majorly driven by the growing awareness among the population regarding early diagnosis and treatment of diseases and the increasing prevalence of chronic diseases. Also, advancements in point of care technologies and diagnostics are expected to boost market growth over the coming years.

With the increase in COVID-19 patients, the testing has expanded across the globe that has stimulated the rise in blood tests being performed and health officials expect a significant increase in the number of people with COVID-19. Therefore as the prevalence of COVID-19 increases, the demand for blood testing also increases that further boost the overall market.

According to the International Diabetes Federation in 2019, there were about 463 million adults that were found living with diabetes and is expected to reach 700 million by 2045. With the rising burden of diabetes and efforts of government and other organizations in increasing awareness among the population is anticipated to boost the market growth over the forecast period.

According to the Regents of the University of California in 2018, there are nearly 750,000 patients per year in the United States alone and the disease disproportionately affects the nation's minority and low-income patients. The estimates have also reported that there are around 2 million people worldwide suffer from end-stage renal disease (ESRD) and the number of patients diagnosed with the disease continues to increase at a rate of 5-7% per year. The countries such as Taiwan, Japan, Mexico, the United States, and Belgium currently have the highest prevalence of ESRD. Therefore the increase in the prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases and emphasis of people on early diagnosis of these diseases are the factors responsible for the growth of the comprehensive metabolic panel (CMP) market.

The rise in demand for point-of-care testing for early detection and faster results by these tests are some of the factors responsible for the growth of the global comprehensive metabolic panel (CMP) testing market.

Key Market Trends

Diabetes Disease Segment is Projected to Grow at a Healthy Growth Rate During the Forecasted Period

Diabetes Disease is one of the fastest-growing diseases that is widening the patient pool for point-of-Care (PoC) CMP testing. The increasing prevalence of diabetes and cardiovascular, and other target diseases, is anticipated to boost the demand for CMP testing over the forecast period.

According to the International Diabetes Federation in 2019, over 463 million adults (20-79 years) were living with diabetes in 2019, and by 2045 this will rise to 700 million. More than 20 million live births i.e. every 1 in 6 live births are affected by diabetes during pregnancy. From these approximately 10-15% of the population have Type 1 diabetes. The rise in prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases and emphasis of people on early diagnosis of these diseases are some of the factors responsible for the growth of the global comprehensive metabolic panel (CMP) testing market

The increase in demand for immediate diagnosis and the advent of new technologies transforming the point of care testing devices thus projected bolster the market growth over the forecast period. Moreover, the introduction and implementation of data-driven solutions in diagnostic for better evaluation of health conditions driving the market growth furthermore.

The kidney diseases segment is also having a notable share in the diseases segment. The share is anticipated to the growing prevalence of kidney disease and increasing emphasis on early diagnosis among the people. Owing to factors such as sedentary lifestyle, changing food habits and increasing diabetic patients around the world, the segment is thus expected to grow at a significant growth rate over the period.

North America is Anticipated to Grow at Significant Growth Rate During the Forecasted Period

North America is projected to continue over the period due to the rising growth of the well-established healthcare infrastructure, the presence of major players, and the presence of a large pool of a patient population.

With the increase in COVID-19, there is a wide range of testing that has been performed on blood and this increase in testing has thus stimulated the overall demand for a comprehensive metabolic panel market in the North America region.

Chronic kidney disease (CKD) has become a public health problem in the United States. According to the CDC data 2019, Chronic Kidney Diseases (CKD) are found to be in 15% of US adults that is around 37 million people suffering from CKD. CKD is more common in people aged 65 years or older (38%) than in people aged 45-64 years (13%) or 18-44 years (7%). CKD is more common in women (15%) compared to men (12%). ​The rise in prevalence of chronic diseases such as kidney diseases, diabetes, and liver diseases are some of the factors responsible for the growth of the global comprehensive metabolic panel (CMP) testing market.

Diabetes is found widening the patient pool for point-of-Care (PoC) CMP testing. Diabetes and high blood pressure are found to be the major causes of CKD in adults. The other risk factors of diabetes include heart disease, obesity, a family history of CKD, past damage to the kidneys, and older age. ​Furthermore, there are favourable reimbursement policies and government support that is anticipated to aid the market growth in the region.

Competitive Landscape

The comprehensive metabolic panel market is moderately competitive having local and international players in the market. Companies are focusing on collaborations and expanding into new geographies to strengthen their market share. The key players operating in this market include Quest Diagnostics, Laboratory Corporation of America Holdings, ARUP Laboratories, Synlab Hrvatska . and UNIPATH among others. These major players are increasingly focusing on strategic initiatives, such as product launches and development, mergers and acquisitions, licensing partnerships, and co-development deals, making this market highly competitive.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Awareness Regarding Early Diagnosis and Treatment of Diseases
    • 4.2.2 Increasing Prevalence of Chronic Diseases
  • 4.3 Market Restraints
    • 4.3.1 Lack of Skilled Professionals
    • 4.3.2 Stringent Regulatory Policies
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Test Type
    • 5.1.1 Proteins
    • 5.1.2 Kidney Tests
    • 5.1.3 Electrolytes
    • 5.1.4 Liver Function Tests
    • 5.1.5 Glucose
    • 5.1.6 Others
  • 5.2 By Disease
    • 5.2.1 Kidney Diseases
    • 5.2.2 Diabetes
    • 5.2.3 Liver Diseases
    • 5.2.4 Others
  • 5.3 By End-User
    • 5.3.1 Point of Care Centers
    • 5.3.2 Laboratories
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States (By Test Type, By Disease, and By End User)
      • 5.4.1.2 Canada (By Test Type, By Disease, and By End User)
      • 5.4.1.3 Mexico (By Test Type, By Disease, and By End User)
    • 5.4.2 Europe
      • 5.4.2.1 Germany (By Test Type, By Disease, and By End User)
      • 5.4.2.2 United Kingdom (By Test Type, By Disease, and By End User)
      • 5.4.2.3 France (By Test Type, By Disease, and By End User)
      • 5.4.2.4 Italy (By Test Type, By Disease, and By End User)
      • 5.4.2.5 Spain (By Test Type, By Disease, and By End User)
      • 5.4.2.6 Rest of Europe (By Test Type, By Disease, and By End User)
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China (By Test Type, By Disease, and By End User)
      • 5.4.3.2 Japan (By Test Type, By Disease, and By End User)
      • 5.4.3.3 India (By Test Type, By Disease, and By End User)
      • 5.4.3.4 Australia (By Test Type, By Disease, and By End User)
      • 5.4.3.5 South Korea (By Test Type, By Disease, and By End User)
      • 5.4.3.6 Rest of Asia-Pacific (By Test Type, By Disease, and By End User)
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC (By Test Type, By Disease, and By End User)
      • 5.4.4.2 South Africa (By Test Type, By Disease, and By End User)
      • 5.4.4.3 Rest of Middle East and Africa (By Test Type, By Disease, and By End User)
    • 5.4.5 South America
      • 5.4.5.1 Brazil (By Test Type, By Disease, and By End User)
      • 5.4.5.2 Argentina (By Test Type, By Disease, and By End User)
      • 5.4.5.3 Rest of South America (By Test Type, By Disease, and By End User)

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Quest Diagnostics
    • 6.1.2 Laboratory Corporation of America Holdings
    • 6.1.3 Sonic Healthcare Limited
    • 6.1.4 SYNLAB International GmbH
    • 6.1.5 Charles River Laboratories, Inc.
    • 6.1.6 ARUP Laboratories.
    • 6.1.7 NeoGenomics Laboratories, Inc.
    • 6.1.8 Genoptix, Inc.
    • 6.1.9 CENTOGENE AG
    • 6.1.10 UNIPATH
    • 6.1.11 Abbott Laboratories
    • 6.1.12 Abaxis Inc. (Zoetis)
    • 6.1.13 TCG Corp
    • 6.1.14 Scion Lab Services, LLC

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top
전화 문의
F A Q